ALLR Allarity Therapeutics, Inc.

Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]

US | NASDAQ | Stock

Price: $0.243

Increased by +4.52%
Dollar Volume: 1.06 M
ADR%: 22.75

Market Cap.: 3.51 M
Shares Float: 9.28 M
Shares Outstanding: 14.43 M

Beta: -0.00
Price / Earnings: -0.06
BPR: 1.61

20D Range: 0.20 0.47
50D Range: 0.20 1.35
200D Range: 0.20 3.33

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 14, 22	-0.68	-0.25 Decreased by -172.00%
Aug 22, 22	-0.52	-0.42 Decreased by -23.81%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	0.00 Decreased by N/A%	-5.04 M Decreased by -685.70%	Decreased by N/A% Decreased by N/A%
Jun 30, 22	0.00 Decreased by N/A%	-4.66 M Decreased by -385.10%	Decreased by N/A% Decreased by N/A%
Mar 31, 22	0.00 -	-4.65 M -	Decreased by N/A% -
Dec 31, 21	0.00 -	-4.97 M -	Decreased by N/A% -
Sep 30, 21	0.00 -	860.00 K -	Increased by +N/A% -
Sep 30, 20	0.00 -	-960.00 K -	Decreased by N/A% -

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.